Clinical Trials

❘❙❚■ Chapter 31 | Interim Monitoring and Stopping Rules3. Pocock SJ. Group sequential methods in the design and analysis of clinical trials.Biometrika 1977;64:191–9.4. O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials.Biometrics 1979;35:549–56.5. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials.Biometrika 1983;70:659–63.6. DeMets DL, Hardy R, Friedman LM, et al. Statistical aspects of early terminationin the beta-blocker heart attack trial. Control Clin Trials 1984;5:362–72.7. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of betacarotene and vitamin A on lung cancer and cardiovascular disease.N Engl J Med 1996;334:1150–5.8. Girling DJ. Comparison of oral etoposide and standard intravenous multidrugchemotherapy for small-cell lung cancer: a stopped multicentre randomised trial.Medical Research Council Lung Cancer Working Party. Lancet 1996;348:563–6.9. Grant AM, Altman DG, Babiker AB, et al; DAMOCLES study group. Issues in datamonitoring and interim analysis of trials. Health Technol Assess 2005;9:1–238.10. DeMets DL, Furberg CD, Friedman L. Data Monitoring in Clinical Trials:A Case Studies Approach. New York: Springer Verlag, 2005.362